ArticleNeurology and therapy2026
Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention; however, real-world data from the Middle East and North Africa (MENA) region remain limited. This study evaluated the efficacy and safety of atogepant in patients with chronic and episodic migraine in the United Arab Emirates.
methodsThis retrospective study included adult patients (≥ 18 years) diagnosed with chronic or episodic migraine who received atogepant for at least 6 months. Clinical data were extracted from electronic medical records at the American Center for Psychiatry and Neurology, Abu Dhabi. Monthly migraine days (MMD) at baseline were compared with follow-up MMD documented at visits occurring at least every 2 months. Safety outcomes were assessed through descriptive analysis of reported adverse events (AEs) in the all-exposed population. Sensitivity analyses (non-responder imputation, baseline observation carried forward, multiple imputation under MAR, and tipping point analysis) were conducted to evaluate the robustness of efficacy results in the presence of missing data.
resultsOf 86 patients identified, 59 met the inclusion criteria and their data were analyzed. Among these, 39% had chronic migraine and 61% had episodic migraine. The majority were female patients (86.4%) and Emirati nationals (69%). The mean baseline MMD was 12 (SD 8.1), which decreased to 4 (SD 5.2) at the most recent follow-up. Overall, 71% achieved ≥ 50% reduction in MMD, 20% achieved < 50% reduction, and 9% experienced no change. Paired-sample t test demonstrated a significant reduction in MMD t(58) = 9.44, p < 0.001. Adverse events were reported in 10.5% (9/86) of patients, most commonly constipation and nausea. Most patients experiencing AEs (78%) continued treatment, while two discontinued.
conclusionIn this real-world cohort from the UAE, atogepant was associated with significant reductions in monthly migraine days in both patients with chronic and episodic migraine and demonstrated a favorable safety and tolerability profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.